Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels

Thrombosis Research

Volumn 156, Issue , 2017, Pages 36-38

  Sabor, Lina ^a   Raphaël, Mélanie ^b   Dogné, Jean Michel ^b   Mullier, François ^a   Douxfils, Jonathan ^b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

Author keywords

Apixaban; Chromogenic anti Xa assays; Edoxaban; Heparin; Rivaroxaban

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EDOXABAN; HEPARIN; RIVAROXABAN; ANTICOAGULANT AGENT;

ATRIAL FIBRILLATION; BLEEDING; CALIBRATION; CHROMOGENIC ANTI XA ASSAY; COAGULOMETER; HEMATOLOGICAL PROCEDURE; HEMATOLOGY TEST KIT; HEMOSTASIS; HUMAN; LETTER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM; BLOOD CLOTTING TEST; PROCEDURES;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; FACTOR XA INHIBITORS; HEPARIN; HUMANS;

EID: 85019984647     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2017.05.024     Document Type: Letter

References (10)

1. Douxfils, J., Mullier, F., Dogne, J.M., Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opin. Drug Saf. 14 (2015), 1283–1289.
2. Douxfils, J., Pochet, L., Lessire, S., Vancraeynest, C., Dogné, J.M., Mullier, F., Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. TrAC Trends Anal. Chem. 84:Part B (2016), 41–50.
3. Gosselin, R.C., Adcock, D.M., The laboratory's 2015 perspective on direct oral anticoagulant testing. J. Thromb. Haemost. 14 (2016), 886–893.
4. Gosselin, R.C., Francart, S.J., Hawes, E.M., Moll, S., Dager, W.E., Adcock, D.M., Heparin-calibrated chromogenic anti-Xa activity measurements in patients receiving rivaroxaban: can this test be used to quantify drug level?. Ann. Pharmacother. 49 (2015), 777–783.
5. Levy, J.H., Ageno, W., Chan, N.C., Crowther, M., Verhamme, P., Weitz, J.I., et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J. Thromb. Haemost. 14 (2016), 623–627.
6. Douxfils, J., Chatelain, B., Chatelain, C., Dogne, J.M., Mullier, F., Edoxaban: impact on routine and specific coagulation assays. A practical laboratory guide. Thromb. Haemost. 115 (2016), 368–381.
7. Harenberg, J., Kramer, R., Giese, C., Marx, S., Weiss, C., Wehling, M., Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J. Thromb. Thrombolysis 32 (2011), 267–271.
8. Beyer, J., Trujillo, T., Fisher, S., Ko, A., Lind, S.E., Kiser, T.H., Evaluation of a heparin-calibrated Antifactor Xa assay for measuring the anticoagulant effect of oral direct Xa inhibitors. Clin. Appl. Thromb. Hemost. 22 (2016), 423–428.
9. Gosselin, R., Grant, R.P., Adcock, D.M., Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int. J. Lab. Hematol. 38 (2016), 505–513.
10. Lessire, S., Douxfils, J., Pochet, L., Dincq, A.S., Larock, A.S., Gourdin, M., et al. Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging. Clin. Appl. Thromb. Hemost., 1076029616675968, 2016.